196 related articles for article (PubMed ID: 35240970)
21. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
[TBL] [Abstract][Full Text] [Related]
22. Nose-to-brain lipid nanocarriers: An active transportation across BBB in migraine management.
Kataria I; Shende P
Chem Phys Lipids; 2022 Mar; 243():105177. PubMed ID: 35122739
[TBL] [Abstract][Full Text] [Related]
23. Intranasal Eutectic Powder of Zolmitriptan with Enhanced Bioavailability in the Rat Brain.
Khan T; Ranjan R; Dogra Y; Pandya SM; Shafi H; Singh SK; Yadav PN; Misra A
Mol Pharm; 2016 Sep; 13(9):3234-40. PubMed ID: 27518323
[TBL] [Abstract][Full Text] [Related]
24. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial.
Dowson AJ; Charlesworth BR; Green J; Färkkilä M; Diener HC; Hansen SB; Gawel M;
Headache; 2005 Jan; 45(1):17-24. PubMed ID: 15663608
[TBL] [Abstract][Full Text] [Related]
25. Intranasal Zolmitriptan-Loaded Bilosomes with Extended Nasal Mucociliary Transit Time for Direct Nose to Brain Delivery.
El Taweel MM; Aboul-Einien MH; Kassem MA; Elkasabgy NA
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834242
[TBL] [Abstract][Full Text] [Related]
26. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
Seaber E; On N; Dixon RM; Gibbens M; Leavens WJ; Liptrot J; Chittick G; Posner J; Rolan PE; Pack RW
Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
[TBL] [Abstract][Full Text] [Related]
27. [Symptomatic treatment of migraine with zolmitriptan: experience with 82 patients].
Pascual J; Navarro A; Caminero AB; Jurado C; Díaz-Insa S; Huerta M
Neurologia; 2006 May; 21(4):188-91. PubMed ID: 16832773
[TBL] [Abstract][Full Text] [Related]
28. Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older.
McKeage K
Paediatr Drugs; 2016 Feb; 18(1):75-81. PubMed ID: 26747634
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of zolmitriptan nasal spray in adolescent migraine.
Lewis DW; Winner P; Hershey AD; Wasiewski WW;
Pediatrics; 2007 Aug; 120(2):390-6. PubMed ID: 17671066
[TBL] [Abstract][Full Text] [Related]
30. Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in vivo preclinical pharmacokinetic study.
Dalpiaz A; Marchetti N; Cavazzini A; Pasti L; Velaga S; Gavini E; Beggiato S; Ferraro L
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jul; 901():72-8. PubMed ID: 22743338
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of submicron emulsion as vehicles for rapid-onset intranasal delivery and improvement in brain targeting of zolmitriptan.
Yu C; Gu P; Zhang W; Cai C; He H; Tang X
Drug Deliv; 2011 Nov; 18(8):578-85. PubMed ID: 21838542
[TBL] [Abstract][Full Text] [Related]
32. Formulation and evaluation of chitosan-chondroitin sulphate based nasal inserts for zolmitriptan.
Kaur K; Kaur G
Biomed Res Int; 2013; 2013():958465. PubMed ID: 24175310
[TBL] [Abstract][Full Text] [Related]
33. Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy.
Jain R; Nabar S; Dandekar P; Patravale V
Pharm Res; 2010 Apr; 27(4):655-64. PubMed ID: 20151180
[TBL] [Abstract][Full Text] [Related]
34. In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug.
Abdou EM; Kandil SM; Morsi A; Sleem MW
Drug Deliv; 2019 Dec; 26(1):689-699. PubMed ID: 31274014
[TBL] [Abstract][Full Text] [Related]
35. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
[TBL] [Abstract][Full Text] [Related]
36. Zolmitriptan: a review of its use in migraine.
Spencer CM; Gunasekara NS; Hills C
Drugs; 1999 Aug; 58(2):347-74. PubMed ID: 10473025
[TBL] [Abstract][Full Text] [Related]
37. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study.
Geraud G; Compagnon A; Rossi A;
Eur Neurol; 2002; 47(2):88-98. PubMed ID: 11844897
[TBL] [Abstract][Full Text] [Related]
38. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine.
Spierings EL; Brandes JL; Kudrow DB; Weintraub J; Schmidt PC; Kellerman DJ; Tepper SJ
Cephalalgia; 2018 Feb; 38(2):215-224. PubMed ID: 29022755
[TBL] [Abstract][Full Text] [Related]
39. Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine.
Zhou W; Li J; Birmingham B; Xu H; Lillieborg S; Zhou D; Al-Huniti N
J Clin Pharmacol; 2017 Oct; 57(10):1258-1267. PubMed ID: 28581633
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study.
Diener HC; Evers S
Clin Drug Investig; 2007; 27(1):59-66. PubMed ID: 17177580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
